Metastasis is the main reason for lung cancer-related mortality, but little is known about specific determinants of successful dissemination from primary tumors and metastasis initiation. Here, we show that CD133
Introduction
Despite novel therapeutic strategies, survival rates for lung cancer have not greatly improved in recent years, mostly due to late diagnosis and limited efficacy of available pharmacologic treatments (1) . Cancer-initiating cells (CIC), functionally defined as the subset of cancer cells responsible for tumor generation and maintenance (2, 3) , could also account for tumor recurrence and metastatic seeding due to their inherent stem-like and chemoresistant properties (4) .
In this context, specific subsets of tumor cells endowed with both stemness and motility properties have been defined as migrating CICs (5, 6) , and activation of the epithelial-to-mesenchymal transition (EMT) process, which is pivotal in metastatic progression, has been shown to modulate stemness properties of cancer cells, indicating a possible connection between external cues and the generation of potential seeds of metastasis (7) (8) (9) . The subset of CICs deputed to tumor dissemination could therefore be specifically modulated by tumor microenvironment stimuli, as recently observed for colon metastatic CICs (10) . Studies in transgenic mouse models also indicate that dissemination is an early event and is supported by tumor cells that have undergone EMT and possess CIC features (11, 12) .
Increasing evidence also shows that chemotherapy might select for intrinsically chemoresistant CICs that could be responsible for primary tumor recurrence (13, 14) . Accordingly, we previously demonstrated that a distinct subset of CD133 þ lung CIC coexpressing the chemokine receptor CXCR4
is spared by cisplatin treatment (15) . The CXCL12/CXCR4 axis plays a crucial role in mediating tumor cell survival and the metastatic process (16) ; more recently, it has been proven to sustain CICs, through activation of self-renewal pathways (17) , and to guide their metastatic dissemination in a human pancreatic tumor model (6) .
In the present study, through the analysis of a variety of lung cancer patient-derived xenografts (PDX; ref. 18 ) and clinical samples, we phenotypically characterize and functionally prove the existence of a novel subset of CICs, regulated by the microenvironment, driving lung tumor dissemination and metastasis and we identify CXCR4 signaling as a potential target for novel therapeutic strategies.
Materials and Methods

List of antibodies
Antibodies used for FACS analysis were anti-human PE CD133/ 1, FITC CD326 (EpCAM) (Miltenyi Biotech); APC CD187 (CXCR4; BD Pharmingen); anti-mouse PerCP-eFluor 710 MHC class I, anti-human PerCP-eFluor 710 CD31 (eBioscience); and anti-human PC5 CD34, PC5 CD45 (Beckman Coulter). Antihuman FITC cytokeratin (CK3-6H5, Miltenyi Biotech) was used for immunofluorescent staining. For IHC analyses, following antibodies were used: anti-human CD133/1 (AC133, Miltenyi Biotech), CXCR4 (CXC-4000-RM, Biotrend), keratin, Pan Ab-1 (Clone AE1/AE3, Dako), CD34 (clone QbndN/10, Neomarkers), and low-molecular-weight cytokeratins (clone AE1/AE3/PCK26, Ventana Medical Systems). Detailed protocols for flow cytometry, immunofluorescence, and IHC staining are in Supplementary Materials and Methods.
Tissue dissociation and culture
Clinical specimens were obtained from a consecutive series of 97 consenting patients (17 also had matching lymph nodes available). The protocol was approved by the Internal Review and the Ethics Boards of the Fondazione IRCCS Istituto Nazionale Tumori of Milan.
The protocol for primary tumors, lymph nodes, PDXs, and murine lungs tissue dissociation was already described (15) . Culture method to obtain cancer tissue-originated spheroids (CTOS) and murine lung tissue spheroids was adapted from Kondo and colleagues (19) . Protocols are detailed in Supplementary Materials and Methods.
Cell lines and treatments
All tumor cell lines were cultured in RPMI with 10% FBS at 37 C under 5% CO 2 . The LT73 primary cell line was derived from a surgical specimen of a male patient with lung adenocarcinoma. The H460 cell line (lung large cell carcinoma) was purchased from ATCC and authenticated by DNA short tandem repeat (STR) profiling.
To induce EMT, cell cultures were treated with TGFb (5 ng/mL; Peprotech) for 5 up to 15 days. CTCE-9908 inhibitor and corresponding scramble control peptide were kindly provided by British Canadian BioSciences Corp. and used for in vitro cell culture treatment at 10 mg/mL for 30 minutes at 37 C in the appropriate growing medium (RPMI-1640 plus 1% FBS or in stem cell medium), before FACS analysis or in in vitro invasion assays, detailed in Supplementary Materials and Methods.
Animal studies
In vivo experiments were approved by the Ethics Committee for Animal Experimentation of the Fondazione IRCCS Istituto Nazionale dei Tumori, according to institutional guidelines.
PDX were established from primary lung cancers from patients undergoing surgical resection, who gave their informed consent and expanded as previously described (18) .
For in vivo combination therapy, cisplatin (Teva Pharma) was administered i.v. at 5 mg/kg every 7 days for 3 weeks, starting when tumors were palpable (!50 mm 3 ). CTCE-9908 was administered i.p. (50 mg/kg) once every 5 days after cisplatin administration for 3 weeks.
A human-in-mice model of bone metastasis was established, as previously reported (20) . A bone metastasis assay was performed by injecting s.c. close to human bone implant 1 Â 10 5 cells sorted from PDX models for CD133 and CXCR4 or by intracardiac (i.c.) route, injecting in the left ventricle 1 Â 10 4 sorted cells in 100 mL physiologic solution. See also Supplementary Materials and Methods.
Integrated strategies to detect disseminating tumor cells in murine lung
To set up the most robust strategy to detect disseminating tumor cells (DTC) in murine lungs, intravenous injection of scalar doses of H460 cells was performed in SCID mice (n ¼ 2 mice for each dose) and lungs were analyzed 2 hours after injection by FACS, real-time PCR, and IHC.
For FACS analysis, injected tumor cells were identified using a negative gating strategy to exclude 7-aminoactinomycin D (7-AAD þ ) dead cells and mouse H2K þ cells that was able to specifically detect as few as 10 3 single tumor cells in murine lungs (Supplementary Fig. S1A and Supplementary Materials and Methods).
For detection of tumor cells in murine lungs by real-time PCR, analysis of human-specific b2 microglobulin (B2M) housekeeping gene expression was performed ( Supplementary Fig. S1B and Supplementary Materials and Methods).
IHC analysis on formalin-fixed, paraffin-embedded (FFPE) lung tissue for pan-cytokeratins (CK) expression was able to robustly identify single cells when injected at 10 4 . To detect lower number of single cells, at least 5 serial sections of FFPE lung tissue, cut at 1.5-mm thickness, had to be analyzed ( Supplementary  Fig. S1C ).
Results
The subset of CD133 þ
CXCR4
þ lung CICs is endowed with increased seeding and metastatic potential To verify the presence of a metastatic subset in lung CICs, we analyzed by FACS 78 primary human non-small cell lung cancer (NSCLC) for CD133 and CXCR4 expression: double-positive cells accounted for 0.3% of total tumor cells (median value range, 0%-8%) and represented 20% of CD133 þ cells (median value 
À cells. n ¼ 13 mice per group at 3 months and n ¼ 7 mice per group at 6 months. ÃÃÃ , P 0.001. C, representative images of hematoxylin and eosin histologic sections of murine lungs scanned with Aperio ePathology System, 6 months after injection of CD133 Fig. S1A-S1C ). Three months after injection, rare tumor cells were detectable in murine lungs and were consistently higher in the groups injected with CD133 Fig. 1B) . After an extended period of time (6 months 
sorted from one PDX model (LT111) and LT73 and H460 cell lines, showed their full metastatic potential and greatest ability to colonize murine lungs compared with other injected groups as reveled by both FACS analysis (4.5-fold increase, Fig. 1D ). A relevant inflammatory infiltrate, mainly consisting of polymorphonuclear leukocytes, was also observed associated with tumor foci (Fig. 1C ) possibly explaining the long latency periods before metastatic cells proliferation. The phenotype of injected double-positive cells remained unchanged during early colonization steps, implying that their survival advantage enables them to support metastasis initiation (Fig. 1E ).
To confirm the high metastatic properties of CD133 þ CXCR4 þ cells and their selective advantage in seeding different organs, we exploited an innovative model of humanized mice implanted with human bone (20, 21) , the second more frequent metastatic site of NSCLC. The implanted human bone, detected in the mouse flank by X-rays examination, was viable as indicated by the presence of bone marrow cells, mineralized areas, stromal cells, and neovascularization ( Fig. 2A) . Unsorted tumor cells and CD133 Table S1 ). Altogether, these results prove the high dissemination and colonization potential of CD133 þ CXCR4 þ cells and their ability to support metastasis development at distant organs.
Inhibition of the CXCR4 pathway prevents metastatic spread of chemoresistant CD133
To block the migration of the CD133 þ
þ metastatic subset, we tested the CXCR4 inhibitor CTCE-9908, a small peptide analogue of SDF-1, previously shown to be effective in preventing metastatic dissemination in different cancer models (22) (23) (24) (25) .
In vitro CTCE-9908 treatment could block invasion of PDXderived tumor cells (n ¼ 4 PDX models) induced by both SDF-1 and FBS (Fig. 3A) . Interestingly, we also verified that the invading fraction of PDXs cells attracted with a nonspecific signal (FBS) was 10-fold enriched in CD133 þ CXCR4 þ cells compared with total population and that CTCE-9908 inhibitor was able to specifically block their invasion (4-fold change; Fig. 3B ), thus pointing at CXCR4 axis as a pivotal mediator of lung CIC invasion.
To test the efficacy of CXCR4 inhibition in a clinically relevant therapeutic setting, we treated in vivo metastatic H460 xenografts with CTCE-9908 in combination with standard chemotherapy. We previously reported that cisplatin treatment, although effective in reducing tumor size, induces enrichment of chemoresistant CICs in the residual tumor (15) . Combination treatment with CTCE-9908 had a similar efficacy in inhibiting subcutaneous tumor growth as cisplatin ( Supplementary Fig. S2A ), but it was able to prevent the relative increase of CD133 þ
þ cells and concomitant upregulation of stemness genes induced by chemotherapy alone ( Fig. 3C and D) . FACS analysis of H460 lung metastases in control mice demonstrated a 10-fold enrichment for CD133 þ CXCR4 þ cells compared with matched s.c. xenograft (P < 0.05), confirming their pivotal role also in the spontaneous metastasis development ( Supplementary Fig. S2B ). Cisplatin treatment primed the dissemination of the CD133 þ CXCR4 þ subset (2-fold change) inducing a boost in metastasis formation (1.8-fold change) compared with control group (Fig. 3E and F ). Combination therapy with CXCR4 inhibitor was able to counteract cisplatin effect, drastically reducing metastatic formation (2-fold decrease) and concomitantly decreasing the subsets of CD133 þ and CD133 þ CXCR4 þ Figure 4 . Supplementary Fig. S2C ). Next, we also proved in a highly disseminating PDX model (LT111) that in vivo combination treatment with CTCE-9908 had a modest effect on tumor growth inhibition ( Supplementary Fig.  S2D ) but was able to prevent tumor spread associated with cisplatin treatment (1.5-fold change) and to efficiently reduce the fraction of disseminated CD133 þ CXCR4 þ CICs to murine lungs (4.7-fold change; Fig. 3G and Supplementary Fig. S2E ).
We additionally verified in cell lines that CXCR4 is also frequently expressed (mean, 70%; range, 50%-90%) in another subset of CICs previously identified as chemoresistant ( of the metastatic cascade, we injected i.v. 1 Â 10 6 unsorted lung tumor cells endowed with different metastatic behavior (LT111-PDX cells, weakly metastatic; LT73 cell line, moderately metastatic; H460 cell line, highly metastatic), and we monitored in time course experiment which tumor cell subsets were preferentially selected to drive specific steps of metastasis development.
Flow cytometric analysis of murine lung 2 hours after injection confirmed the presence of tumor cells that maintained the same phenotype of original tumor cells (Supplementary Fig. S3A ). After 1 week, the number of tumor cells drastically decreased (20-fold) with a concomitant enrichment for the CD133 þ
þ subset in the surviving tumor fraction (Fig. 4A) . We also detected in LT73 and LT111 surviving cells a significant increase for a fraction of CD133 þ CICs negative for the expression of epithelial antigen EpCAM compared with parental injected tumor cells (18-fold increase), whereas the parental H460 cell line does not express at all EpCAM marker (Fig. 4A) . Surviving LT111 cells remained in murine lung, without proliferating, for up to 3 months and stably showed enrichment for CD133 (Fig. 4A) . Conversely, during metastatic growth of LT73 and H460 cells, both subsets of CD133 þ CXCR4 þ and CD133
þ EpCAM À cells, diminished and reverted to the original percentage of the parental cell line when metastases reached macroscopic size ( Fig. 4A and Supplementary Fig. S3B ). Expression of stemness genes followed the same trend of CD133 þ CXCR4 þ cells in the different phases of metastatic development (Fig. 4B) . In summary, these findings confirm the primary role of CD133
þ CICs in metastasis process, due to a superior survival advantage and colonization ability, and reveal the existence of the CD133 þ EpCAM À subset strongly enriched in early steps of colonization. While generally no histologic metastases were evident, FACS analysis was able to detect a subset of DTCs in 9 of 11 PDX models (n ¼ 6 adenocarcinoma; 1 large cell carcinoma, LCC; 2 squamous cell carcinoma models, SCC), in a percentage (range, 0.001%%-0.01%) consistent with that estimated from human B2M expression by qRT-PCR (data not shown).
Lung DTCs were already detectable at early stages of subcutaneous tumor development and remained stable during tumor growth ( Supplementary Fig. S4A ). Notably, immunophenotyping of lung DTCs revealed a constant increase for the fraction of CD133 
þ EpCAM À cells represented the CIC subset more significantly enriched in the invading fraction compared with total population (90-fold, P ¼ 0.01; Fig. 5A ).
To functionally characterize the subset of lung DTCs enriched in disseminating CICs, we adapted an in vitro culture method useful to enrich for tumor cells (19) ; from 6 different PDXs (4 adenocarcinoma, 1 SCC, 1 LCC), we generated cultures of CTOS and corresponding lung tissue spheroids, highly enriched in DTCs compared with freshly dissociated lung tissue (range, 70-to 145-fold increase) as also confirmed by qRT-PCR analysis for hB2M expression and by staining for human cytokeratins (Fig. 5B and Supplementary Fig. S4C ).
Real-time analysis of lung spheroids cultures showed a strong upregulation for stemness genes and for a panel of EMT-related genes in DTCs compared with matching PDX-CTOS, subtending an enrichment for the subset of CD133 þ stem-like cells endowed with mesenchymal features (i.e., EpCAM À ; Fig. 5C ).
To functionally test tumorigenic properties of DTCs, we s.c. injected in NOD-SCID mice 1 Â 10 5 lung spheroids dissociated cells, containing approximately 200 DTCs and 1 Â 10 5 PDX-CTOS dissociated cells generated from LT59 PDX. DTCs were able to originate tumors that closely resembled histology and phenotype of original PDX (Fig. 5D ) but contained a larger amount of (Continued.) Mouse B2m endogenous control gene is equally expressed between samples. C, relative quantification of stemness genes (left) and EMT-associated genes expression (right) in lung DTCs compared with corresponding PDX-CTOS, used as calibrators (n ¼ 2 independent experiments). D, hematoxylin and eosin of PDX and corresponding DTC tumor, derived from s.c. injection of lung spheroids (magnification, Â20 and Â40). E, flow cytometric analysis of LT59 tumor from CTOS and DTCs indicating the enrichment for the CXCR4 
þ EpCAM À cells compared with parental xenograft (Fig. 5E) . Moreover, cells from DTC tumors maintained a slightly increased expression of EMT-related genes compared with CTOS tumors and exclusively possessed the ability to proliferate in vitro as spheres in anchorage-independent condition (Supplementary Fig. S4D and S4E) . Remarkably, in vivo s.c. injection of cells from DTC tumors demonstrated an enhanced ability to generate secondary tumors (Fig. 5F ) and higher lung dissemination ability compared with CTOS tumor (disseminated tumor cells: 0.6% AE SD 0.1 vs. 0.09% AE SD 0.03; Fig. 5G) .
Finally, intravenous injection of LT59 lung spheroids dissociated cells ($200 DTCs) in NOD-SCID mice generated lung metastases, which again showed an increased fraction CD133
À cells, whereas up to 1 Â 10 5 LT59 cells and LT59-CTOS cells failed to initiate metastasis (Fig. 5H) .
Our evidence proves the existence of an invasive and highly tumorigenic CD133 þ CXCR4
þ EpCAM À subset that specifically drives lung tumor dissemination.
Microenvironment stimuli modulate the subset of CD133
The mesenchymal properties displayed by CD133 Fig. 6C) .
In PDXs and primary CTOS cultures (n ¼ 5), EMT induced by TGFb was able to enrich for
nating CICs (15-fold change, P ¼ 0.05; Fig. 6D and Supplementary Fig. S5G ), associated with an increased in vitro invasiveness and upregulation of EMT and stemness genes ( Supplementary  Fig. S5H and S5I ).
To evaluate whether the CIC enrichment was due to an expansion of the pre-existing CD133 þ pool or to de novo generation, we depleted CD133 þ cells by FACS from the LT73 cell line, creating the LT73-CD133 À line that stably maintained a CD133 À phenotype during in vitro culturing (Fig. 6E) . TGFb treatment of LT73-CD133 À cells induced the generation of a fraction of CD133 þ cells (mean AE SD, 0.14% AE 0.05%), similar to that observed in LT73 parental cells (mean AE SD, 0.09% AE 0.02%), that however exhibited a lower expression of EpCAM compared with endogenous CD133 þ cells (Fig. 6E) . Upon TGFb withdrawal, LT73-CD133 À cells slowly reverted to an epithelial phenotype, whereas the fraction of de novo generated mesenchymal CD133 þ cells persisted, indicating a stable reprogramming ( Fig. 6E and Supplementary Fig. S5L and S5M ). Consistently, tumors derived from s.c. injection of LT73-CD133 À EMT appeared with a shorter latency period than LT73-CD133 À cells
and maintained a similar fraction of de novo generated CD133 þ cells ( Supplementary Fig. S5N and S5O).
To verify whether physiologically relevant tumor microenvironment stimuli could show similar proficiency in generating lung CICs, LT73-CD133
À cells were cocultured with conditioned medium (CM) from cancer-associated fibroblasts (CAF) isolated from primary human lung tumors. A variable but constantly detectable fraction of de novo CD133 þ cells was observed after exposure to different CMs, mirrored by a parallel modulation of EMT genes ( Fig. 6F and G) indicating that also stimuli from microenvironment are able to endow tumor cells with mesenchymal traits associated with CIC generation. Because stromal SFD-1 has been proven to induce EMT activation in different tumor types (27, 28) , we explored the role of SDF-1 as a possible mediator of CAF effects on tumor cells. In line with reported evidence, we confirmed that in vitro treatment of the LT73 cell line with SDF-1 resulted in upregulation of EMT genes ( Supplementary Fig. S5P ). Treatment of LT73-CD133
À cells with CMs and CXCR4 inhibitor CTCE-9908 demonstrated a partial prevention of EMT genes modulation compared with CMs alone, thus confirming that SDF-1 represents one of the CAF-secreted factors that mediate EMT activation in tumor cells (Fig. 6G ). CM-generated CD133 þ CICs were functionally associated with an enhanced in vivo tumorigenicity compared with untreated CD133 À cells (Fig. 6H) , and interestingly, the ensuing xenografts displayed a CD133 fraction reflecting the proficiency of CAF-CMs to create CICs in vitro (Fig. 6I) . Notably, the relative percentages of
À tumors correlated with their disseminating potential to murine lungs ( Fig. 6I and J) . 
Discussion
Although metastasis has generally been considered a multistep process requiring acquisition of specific genetic alterations providing tumor cells with crucial advantages (29) , plasticity is gaining attention as a fundamental trait for metastasis-prone tumors, and the identification of definite phenotypes linked to this process appears crucial for its understanding (30) .
Here, we demonstrate that the subset of CD133
CICs drives tumor cells seeding and metastasis initiation in lung cancer. The high metastatic potential of CD133
and their enhanced ability to seed and colonize different organs (i.e., lung and bone) is substantiated in experimental lung metastasis as well as in an humanized murine model of bone metastasis: interestingly, in such an experimental model, the presence of a "human pre-metastatic niche" represented by implanted bone is conductive for generation of overt metastases in a considerable shorter time than in an experimental metastasis assay, stressing the importance of proficient niche to support and dictate tumor development and the challenge of recapitulating the human microenvironment in mouse (31) (32) (33) 
CXCR4
þ EpCAM À CIC subset, demonstrating in a clinical setting, the relevance of this subpopulation in metastasis formation. The mesenchymal features of disseminating tumor cells as well as the well-known link between EMT activation and acquisition of invasiveness and stem-like features prompted us to investigate the possible involvement of EMT in their generation (7, 36, 37) . Our data indeed confirmed that EMT triggering generates CD133 þ cells and, more interestingly, we demonstrated for the first time that stimuli from tumor microenvironment, specifically those from CAF, could dictate de novo creation of the CD133 þ CXCR4
þ EpCAM CIC subset directly linked to EMT induction and acquisition of in vitro and in vivo increased dissemination. Similar data proving the capability of microenvironmental stimuli to convert progenitor cells into cancer stem cells with metastatic properties are reported in colon cancer (10) .
Moreover our finding showing that CAF-secreted SDF-1 promotes EMT activation and likely the acquisition of stemness features in lung tumor cells, in line with evidence reported in colorectal cancer (27) , strengthens the potential therapeutic use of CXCR4 inhibitor to prevent both dissemination of metastatic CICs and their generation through the impairment of tumorstroma cross-talk.
The clinical relevance of our findings was demonstrated by the fact that the frequency of CD133
EpCAM
À within the CIC pool in primary tumors represents an independent indicator of poor prognosis in surgically resected NSCLC patients, suggesting that dissection of the biologic complexity of primary tumors will be crucial to improve clinical management of lung cancer. The prospective to identify the fraction of metastatic CD133 þ CXCR4 þ CICs negative for EpCAM expression in circulating tumor cells from patients with lung cancer holds therefore great interest and implications from both a prognostic and therapeutic point of view, as recently highlighted in patients with breast cancer where isolated EpCAM À circulating tumor cells showed high invasiveness and ability to generate brain and lung metastases (38) (39) (40) .
In conclusion, we provide evidence for the existence of novel human lung disseminating CICs regulated by microenvironmental signals able to complete all the steps of the metastatic cascade and related to clinical recurrence. We also propose CXCR4 targeting as a novel therapeutic option in neoadjuvant and adjuvant setting to counteract the dissemination of chemoresistant and metastatic lung CICs.
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